Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
In Reply.— In response to Dr Grush's
concern about the extent of SSRI exposure, all 267 women in the study took
SSRIs during embryogenesis. All 3 drugs we studied interact with the same
neurotransmitters, and it makes biological sense to combine them. With the
availability of larger sample sizes in the future, it will be possible to
achieve enough power for each drug separately.
Dr Witlin asserts that women who call teratogen information services
represent those with milder forms of depression. This does not hold true based
on our recent studies in which depression was quantified.1
Moreover, because the study aimed at assessing the effects of the drugs, milder
depression, even if it exists, is not necessarily a "skew" but rather occurs
in a group with fewer confounding factors.
Koren G. Risk of Fetal Anomalies With Exposure to Selective Serotonin Reuptake Inhibitors—Reply. JAMA. 1998;279(23):1873. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-23-jbk0617